METHYLLYCACONITINE CITRATE
|
|
- CAS号:
- 351344-10-0
- 英文名:
- Methyllycaconitine (citrate)
- 英文别名:
- 中文名:
- METHYLLYCACONITINE CITRATE
- 中文别名:
- 甲基牛扁亭柠檬酸盐;化合物 T12017
- CBNumber:
- CB94666704
- 分子式:
- C43H58N2O17
- 分子量:
- 874.93
- MOL File:
- 351344-10-0.mol
|
|
|
METHYLLYCACONITINE CITRATE化学性质
-
储存条件:
-
Desiccate at -20°C
-
|
-
溶解度:
-
Water: Soluble
-
|
-
形态:
-
A solid
-
|
METHYLLYCACONITINE CITRATE性质、用途与生产工艺
Methyllycaconitine citrate 是 α7 神经元烟碱型乙酰胆碱受体 (α7nAChR) 的特异性拮抗剂。
Pretreatment with 5 and 10 µM Methyllycaconitine citrate (MLA) inhibits the decreased cell viability induced by Aβ
25-35
. Cell viability does not decrease after exposure to Methyllycaconitine citrate (2.5, 5, 10, 20 µM). Aβ
25-35
treatment increases LC3-II levels, which is inhibited by administration of Methyllycaconitine citrate. Methyllycaconitine citrate also inhibits Aβ-induced autophagosome accumulation in SH-SY5Y cells. Flow cytometry also demonstrates decreased MDC-labeled vacuoles with Methyllycaconitine citrate treatment.
Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with Methyllycaconitine citrate significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%. Methyllycaconitine citrate does not modify either basal locomotor activity or METH-induced hyperlocomotion. The METH-induced depletion of dopamine neuron terminals is attenuated in mice pretreated with Methyllycaconitine citrate (250±43 fmol/mg, n=7). A direct effect of Methyllycaconitine citrate on body temperature is ruled out because Methyllycaconitine citrate does not affect basal body temperature (37.0±0.5°C, n=5) or reduce the METH-induced hyperthermia (38.2±0.4°C, n=6, MLA+METH group, n.s. versus METH group).
METHYLLYCACONITINE CITRATE
上下游产品信息
上游原料
下游产品
METHYLLYCACONITINE CITRATE
生产厂家
351344-10-0, METHYLLYCACONITINE CITRATE 相关搜索:
- 化合物 T12017
- 甲基牛扁亭柠檬酸盐
- 351344-10-0